Boehringer Ingelheim is continuing to explore its newfound enthusiasm for eye health, penning a $1 billion biobucks pact with ...

Decentralized Clinical Trials (DCTs) are transforming how we collect clinical data, but this evolution brings unprecedented challenges in data quality, complexity, and integration.

Atai Life Sciences’ schizophrenia drug has failed to improve cognition in a phase 2 study, leading the biotech to reaffirm ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

Having recently scored approval for Nucala in chronic obstructive pulmonary disease (COPD), GSK has now signed a major ...

Olympus has teamed up with Revival Healthcare Capital to launch a joint venture aimed at bringing robotics to gastrointestinal procedures.  | Swan EndoSurgical plans to develop a minimally invasive, ...

Chinese biotech company Leads Biolabs has hit the Hong Kong stock exchange, snagging $189 million through an initial public offering on the HKEX. | Chinese biotech Leads Biolabs has hit the Hong Kong ...

Roche has obtained European approval for a blood test to help rule out Alzheimer’s disease, allowing patients to avoid additional exams for the condition after showing signs of cognitive | According ...

Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer, persuading Cristian Massacesi, M.D., to ...

Roche’s move came against a backdrop of wider industry retreat from gene therapy, with Pfizer pulling its FDA-approved ...

Ikena and Inmagene have selected Kristin Yarema, Ph.D., to lead the company upon the anticipated closing of their merger.

A phase 2 trial of Memo Therapeutics’ kidney transplant drug candidate has missed its primary endpoint, adding to the list of ...